Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015713
Filing Date
2024-11-14
Accepted
2024-11-14 16:10:32
Documents
91
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cara-20240930x10q.htm   iXBRL 10-Q 2829716
2 EX-3.2 cara-20240930xex3d2.htm EX-3.2 211317
3 EX-31.1 cara-20240930xex31d1.htm EX-31.1 12311
4 EX-31.2 cara-20240930xex31d2.htm EX-31.2 11351
5 EX-32.1 cara-20240930xex32d1.htm EX-32.1 11223
  Complete submission text file 0001558370-24-015713.txt   10836097

Data Files

Seq Description Document Type Size
6 EX-101.SCH cara-20240930.xsd EX-101.SCH 69481
7 EX-101.CAL cara-20240930_cal.xml EX-101.CAL 54226
8 EX-101.DEF cara-20240930_def.xml EX-101.DEF 322170
9 EX-101.LAB cara-20240930_lab.xml EX-101.LAB 549307
10 EX-101.PRE cara-20240930_pre.xml EX-101.PRE 472848
94 EXTRACTED XBRL INSTANCE DOCUMENT cara-20240930x10q_htm.xml XML 1872140
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36279 | Film No.: 241462211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)